This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.
Ensign Group (ENSG) Buys Facilities in Arizona & Colorado
by Zacks Equity Research
Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Here's Why Enovis (ENOV) is Poised for a Turnaround After Losing -17.45% in 4 Weeks
by Zacks Equity Research
Enovis (ENOV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -15.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Enovis (ENOV)
by Zacks Equity Research
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis (ENOV) Q1 Earnings Match Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biotricity Inc. (BTCY) delivered earnings and revenue surprises of 17.07% and 0.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.28% and 2.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Why Community Health (CYH) Shares Are Attracting Investors Now
by Zacks Equity Research
We expect Community Health's (CYH) occupancy rate to continue moving upward, reflecting improving utilization of its facilities and services.
Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada
by Zacks Equity Research
The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.
Reasons to Retain HCA Healthcare (HCA) Stock in Your Portfolio
by Zacks Equity Research
HCA Healthcare's (HCA) improving top line, acquisition initiatives and a robust growth outlook poise the company well for growth.
Why You Should Retain Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, growing medical membership and a positive 2023 outlook poise it well for growth.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Ensign Group (ENSG) Sanctions 4% Quarterly Dividend Hike
by Zacks Equity Research
Ensign Group (ENSG) announces a dividend hike, underlining a strong financial position and continued focus on deploying capital to shareholders.
Here's Why Investors Should Hold Elevance (ELV) Stock for Now
by Zacks Equity Research
Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.
Centene (CNC) Unveils its 2024 Projections: Key Takeaways
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $4 billion fund.
Cigna (CI) Adds $10B to Buyback Funds, Turns to Bolt-On Buyouts
by Zacks Equity Research
Cigna (CI) expects to maintain average annual adjusted EPS growth within 10-13% in the long term.
Evaluating Acadia Healthcare's (ACHC) Future View: Hold or Fold?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to capitalize on increasing patient days and bed capacity.
HCA Healthcare's (HCA) Houston Affiliate Acquires 11 EDs
by Zacks Equity Research
The deal helps HCA Healthcare (HCA) boost its freestanding EDs in the Houston region to 26, supplementing its existing hospital-based emergency rooms.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
How Much Upside is Left in Enovis (ENOV)? Wall Street Analysts Think 38.3%
by Zacks Equity Research
The mean of analysts' price targets for Enovis (ENOV) points to a 38.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.